Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Randomized Phase III Trial of Neo-adjuvant Chemotherapy Followed by Surgery and Chemotherapy or by Surgery and Chemoradiotherapy in Resectable Gastric Cancer (CRITICS Study: ChemoRadiotherapy after Induction chemoTherapy In Cancer of the Stomach)

Next Previous
Trial Profile

A Multicenter Randomized Phase III Trial of Neo-adjuvant Chemotherapy Followed by Surgery and Chemotherapy or by Surgery and Chemoradiotherapy in Resectable Gastric Cancer (CRITICS Study: ChemoRadiotherapy after Induction chemoTherapy In Cancer of the Stomach)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Cisplatin; Epirubicin
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms CRITICS

    • Most Recent Events

    • 18 Jul 2022 Results assessing differences in clinicopathological characteristics and survival in microsatellite instability (MSI)-high and microsatellite stable (MSS) gastric cancer , published in the European Journal of Cancer.
    • 09 Feb 2022 This trial has been completed in Sweden, according to European Clinical Trials Database record.
    • 20 Nov 2020 Results of per-protocol analysis of this trial, published in the Annals of Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top